Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT04964934
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04946864
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
🇺🇸MD Anderson, Houston, Texas, United States
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT04872608
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT04870034
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- Conditions
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 895
- Registration Number
- NCT04862663
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04858997
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Haihe Biopharma Co., Ltd.
- Target Recruit Count
- 228
- Registration Number
- NCT04856371
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 96
- Registration Number
- NCT04841148
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.